Hikma Publishes Transcript of R&D Spotlight on Respiratory, Nasal, Semi-Solids and Liquids

• Hikma’s October 20, 2026, respiratory, nasal, semi-solids and liquids R&D spotlight featured global R&D head Hafrun Fridriksdottir and platform head Chris Edlin.
• Intranasal epinephrine is under US regulatory review, with FDA feedback expected in the first half of 2027.
• Respimat submission timing has slipped following technical challenges, but management does not expect a material impact on launches targeted around patent expiry.
• The Ellipta program has generated human data supporting device selection; commercial manufacturing capability is being established in Columbus.
• Higher R&D investment targets opportunities across three platforms, including a greater focus on first-to-file and first-to-market solid oral products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.